Eamon & Bec on MSN
Her nerve damage became serious enough to change her final chemo dose
Even on the eve of her final chemotherapy session, treatment still brings difficult decisions. Bec’s neuropathy has become ...
Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and ...
Memory Loss and Concentration Problems During Cancer Treatment / brain fog, Cancer Fatigue, cancer related cognitive ...
The FDA’s approval of daraxonrasib marks a significant development in pancreatic cancer treatment, with clinical trial ...
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free ...
ABC News' correspondent Will Reeve is opening up for the first time about receiving a cancer diagnosis just months after getting married. Reeve, 34, said his wife, Amanda, whom he wed in January, ...
Global Urothelial Cancer Drugs Market was valued at USD 4.03 Billion in 2025 and is expected to grow at 11.34% CAGR to reach USD 11.81 Billion by 2035.
Authorities are sealing a private clinic in Thessaloniki after inspectors found it operated an unauthorized oncology unit.
After 3 rounds of chemotherapy, the 59-year-old patient vomited, had diarrhea, and became exhausted. Thinking of the side ...
How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages Northwestern University economist ...
HUTCHMED said Tuesday that partner AstraZeneca (AZN) has submitted a New Drug Application to the US Food and Drug Administration for the lung-cancer fighting drugs Orpathys plus T ...
Limited announced that AstraZeneca has submitted a New Drug Application (?NDA?) to the US Food and Drug Administration (?FDA?) for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results